Xeris Biopharma Holdings, Inc. officer Beth Hecht filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 75,000 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: 75,000 shares of Xeris Biopharma Holdings common stock with an aggregate market value of $803,250.00.
  • Seller: Beth Hecht, identified as an officer of the issuer.
  • Source of shares: Restricted stock units acquired from the issuer, with the filing noting they vested during the period of January 3, 2025 through January 31, 2025.
  • Approximate sale date: November 2, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • 10b5-1 plan adoption date: May 12, 2026, as indicated on the notice.
  • Shares outstanding: 182,320,306 shares of common stock outstanding at the time of filing, according to the notice.
  • Prior sales in last 3 months: Three prior 10b5-1 sales of 16,666 shares each on August 3, September 1, and October 1, 2026, totaling gross proceeds of $431,779.06 combined.

Xeris Biopharma Officer Beth Hecht Discloses Planned Rule 144 Stock Sale

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Beth Hecht, an officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), proposed to sell 75,000 shares of common stock at an aggregate market value of $803,250.00. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the broker for the proposed transaction.

The filing states that the securities to be sold were acquired through restricted stock units granted by the issuer. According to the notice, acquisition of the shares is dated January 3, 2025, with payment dated January 3, 2025, and the remarks section specifies that the units vested "during the period of 1/3/2025 through 1/31/2025." The proposed sale is described as part of a written trading plan relying on Rule 10b5-1, adopted on May 12, 2026.

The notice also discloses three prior sales by Beth Hecht under 10b5-1 during the preceding three months: 16,666 shares sold on August 3, 2026, for gross proceeds of $133,553.66; 16,666 shares sold on September 1, 2026, for gross proceeds of $141,433.67; and 16,666 shares sold on October 1, 2026, for gross proceeds of $156,791.73. All three prior sales were of common stock and listed the issuer's address in Chicago, Illinois. The total shares outstanding reported in the filing are 182,320,306.

What Was Disclosed

Xeris Biopharma Holdings officer Beth Hecht filed a Form 144 notice proposing to sell 75,000 shares of common stock valued at $803,250.00 on November 2, 2026, under a 10b5-1 plan adopted May 12, 2026, with shares sourced from vested restricted stock units.